Sanofi India Limited and Sanofi Healthcare India Private Limited (SIL) and Cipla Limited announced an exclusive partnership for distribution and promotion of Sanofi India's Central Nervous System (CNS) product range in India. As a part of this partnership, Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium®, a leading brand in the anti-epileptic medication category. While Sanofi India will continue to own, import, and manufacture its complete range of CNS products across plants in India and internationally, Cipla will leverage its capabilities and robust India-wide network of strong marketing and sales professionals, distributors, institutions, and market outreach programs to expand access to these treatments for patients who need them.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,340 INR | -1.42% | -5.98% | +7.48% |
May. 10 | Transcript : Cipla Limited, Q4 2024 Earnings Call, May 10, 2024 | |
May. 10 | Market Heavyweights Lifts Indian Equities to End Week Higher | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
7,951 INR | -1.76% | -7.72% | 2.19B | ||
1,340 INR | -1.42% | -5.98% | 12.95B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.48% | 12.95B | |
+19.62% | 43.27B | |
+24.52% | 22.92B | |
+20.29% | 15.43B | |
+42.51% | 11.83B | |
-8.84% | 6.91B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+13.13% | 5.55B | |
+9.14% | 4.9B |
- Stock Market
- Equities
- CIPLA Stock
- News Cipla Limited
- Sanofi India Limited, Sanofi Healthcare India Private Limited and Cipla Limited Announce an Exclusive Partnership